Tagged Articles

AbbVie 91 articles

Whistleblower Suit Against Abbott, AbbVie Recovers $25 Million For U.S. Taxpayers

Abbott Laboratories and AbbVie Inc. have agreed to pay more than $25 million to settle a long-standing whistleblower lawsuit claiming the drug companies illegally promoted the triglyceride drug TriCor for off-label purposes and provided doctors and other prescribers with unlawful kickbacks to boost sales. Amy Bergman, a former Abbott sales representative, filed the lawsuit under the whistleblower provisions of the False Claims Act in 2009. The U.S. Department of Justice declined to intervene in the case, but it moved ahead without the government’s direct involvement, surviving attempts by Abbott and AbbVie to have the case thrown out. According to the ... Read More

Fewer men using testosterone therapy following FDA warnings

Fewer men in the United States are using testosterone replacement therapy following a stark decrease from 2013 to 2016 over concerns with over-prescribing and health risks, according to researchers with the University of Texas Medical Branch at Galveston. Testosterone treatments, including AbbVie’s Androgel, were heavily touted by drug companies as cure-alls for so-called Low T, a contrived condition caused by an age-related drop in testosterone levels that leads to symptoms such as low sex drive, weight gain, muscle loss and fatigue. The ad campaign resulted in hundreds of thousands of prescriptions for the male hormone supplement. Testosterone replacement therapies are ... Read More

AbbVie testosterone case to be retried

An Illinois federal judge has ordered a retrial of the second bellwether in a multidistrict litigation alleging testosterone replacement therapy makers failed to warn about cardiovascular risks with their products. In October, plaintiff Jeffrey Konrad was awarded $140,000 in compensatory damages and $140 million in punitive damages after he blamed AbbVie’s AndroGel for causing his heart attack. But U.S. District Judge Matthew Kennelly found that the jury’s finding of strict liability clashed with Konrad’s negligence claim. At issue is the instructions given to the jury for strict liability and negligence claims, both of which required the jury to find that ... Read More

Actavis poised to settle testosterone side effects lawsuits

Actavis Inc., a pharmaceutical company named in a multidistrict litigation (MDL) alleging failure to warn of cardiovascular risks with testosterone replacement therapies, has reached a memorandum of understanding on a potential global settlement concerning its testosterone treatment Androderm. Actavis is the latest testosterone manufacturer to make a move toward exiting the MDL, following similar measures by Auxilium Pharmaceuticals LLC, Eli Lilly & Co., Endo Pharmaceuticals PLC, and GlaxoSmithKline LLC. AbbVie is the only drug company in the MDL that has yet to make an effort to resolve outstanding cases. The AndroGel manufacturer also faces the most lawsuits in the litigation. ... Read More

AbbVie faces more lawsuits in testosterone MDL

AbbVie Inc., prevailed in the latest bellwether trial accusing the company’s testosterone treatment AndroGel of causing heart attacks, strokes and blood clots, but AbbVie and other testosterone manufacturers still face thousands more lawsuits consolidated in a multidistrict litigation in the U.S. District Court for the Northern District of Illinois. This is the third of five bellwether trials that have been won by testosterone makers. The other two have resulted in a total of $143 million in verdicts for the plaintiffs. The latest trial involved the case of Rober Rowley who was prescribed AndroGel in 2012 to treat fatigue. Years earlier, ... Read More

Besins released from testosterone MDL

Thailand-based Besins Healthcare SA, which manufactures the topical testosterone treatment AndroGel outside the United States, was released from a multidistrict litigation (MDL) involving several manufacturers of testosterone replacement therapies. Besins licensed exclusive right to market and distribute AndroGel in the U.S. to AbbVie. U.S. District Judge Matthew F. Kennelly dismissed all remaining claims against Besins after finding that plaintiffs did not allege that the company had a responsibility to conduct safety tests of AndroGel in the U.S. AbbVie and other testosterone makers are facing about 6,500 of claims in a multidistrict litigation centralized in the Northern District of Illinois. Most ... Read More

AbbVie faces fourth testosterone side effects trial

AbbVie Inc. will continue to use deceptive practices to market its testosterone replacement therapy AndroGel unless it is sent a firm message and faces financial pressure, say attorneys for a man who blames his heart attack on the drug. The jury in the fourth bellwether trial against AbbVie in a multidistrict litigation heard testimony alleging testosterone manufacturers did not adequately warn of cardiovascular risks with their testosterone treatments. Jesse Mitchell’s case was the first to go to trial and accuse AbbVie of failing to warn that AndroGel could increase the risk of heart attacks, strokes and blood clots, some of ... Read More

FDA assists in Zinbryta MS drug’s removal from U.S. market

A week after drug makers Biogen and AbbVie announced they were pulling the multiple sclerosis (MS) drug Zinbryta from markets worldwide because the medication had been linked to severe liver damage and brain inflammation, the Food and Drug Administration (FDA) announced it planned to assist the drug companies with the management of the withdrawal in the U.S. Zinbryta, known chemically as daclizumab, was approved to treat relapsing MS in the European Union, the United States, Switzerland, Canada, and Australia. Most of the 8,000-plus people treated with Zinbryta live in Germany. The companies announced the withdrawal of Zinbryta after receiving eight ... Read More

Three drug makers reach tentative settlement in testosterone side effects MDL

Three manufacturers of testosterone replacement therapies among several in a multidistrict litigation accusing the companies of failing to warn consumers about cardiovascular risks with their products, have notified an Illinois federal judge that they have reached a tentative deal to settle the cases in which they are named. U.S. District Judge Matthew Kennelly told the manufacturers – Endo Pharmaceuticals Inc., Auxilium Pharmaceuticals LLC and GlaxoSmithKline LLC – that he would place a 45-day stay on the cases against them while the details of the settlement are worked out. He also told the remaining defendants – including AbbVie Inc., and Actavis ... Read More

Patient asks that new AndroGel side effects trial be on all claims

Jesse Mitchell asked an Illinois federal court to order a new trial on all his claims against testosterone manufacturer AbbVie Inc., instead of just one claim in the first bellwether in a multidistrict litigation accusing makers of testosterone replacement therapies of misrepresenting their products and failing to warn that their treatments were linked to cardiovascular risks. Jurors in that case did not find Abbie’s AndroGel as the cause of Mitchell’s heart attack, but did find the company guilty of fraudulently misrepresenting the testosterone treatment through alleged off-label marketing. As a result, they awarded Mitchell no compensatory damages, but did award ... Read More